论文部分内容阅读
我国与日本在生物工程领域的发展与专利审查标准方面具有一定的相似性。针对具体的蛋白质产品而言,两国创造性的判断标准基本相同,而新颖性的判断中除中国规定的一种情形外,日本进一步规定与已知蛋白质氨基酸序列相同、但糖链等不同的蛋白质具有新颖性。我国第15463号无效审查案例以及日本平成14年第505号判例中体现了中日对于蛋白质产品新颖性和创造性的审查标准,对未来该方面问题的认定具有一定指导意义。
China and Japan have certain similarities in the field of bioengineering and patent examination standards. In terms of specific protein products, the creative judgment standards of the two countries are basically the same. However, in addition to the case of China stipulated in the novelty judgment, Japan further stipulates the same amino acid sequence as the known protein but different proteins such as sugar chains With novelty. China’s No. 15463 invalid review case and Japan’s No. 505 judgment in 1990 represent China and Japan’s review standards for the novelty and creativity of protein products, which are of guiding significance for the future identification of this issue.